This trial has been cancelled. Clinical trials may be cancelled prior to commencement, or during the course of the trial, for a number of reasons – these may be summarised below. You cannot enrol in this trial.
This is a study to assess long-term safety and efficacy(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. of lersivirine in people who have already completed 96 weeks of treatment with lersivirine in studies A5271015 and A5271022.
A Long Term Open-Label Extension Study of Lersivirine For The Treatment Of HIV-1 Infection
new_drug – efavirenz, etravirine (TMC-125), UK-453,061
March 2011 (This may be the proposed or expected start date for trials which have not yet started.)
Participants in this trial will be asked to take the trial drugs for 240 weeks.
You may be eligible to participate in this trial if you meet the following criteria:
This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.
While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.
Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.
Contact NAPWA if you have any questions or comments about this trial.